The latest research study “Antihyperlipidemic Drugs Market Market Growth: Global Industry Trends, Share, Size, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global antihyperlipidemic drugs market reached a value of US$ 11.31 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 15.81 Billion by 2027, exhibiting a CAGR of 5.20% during 2022-2027.
Antihyperlipidemic drugs are used to lower serum levels of cholesterol in the blood. They are prescribed along with different medications to control the lipid level in the blood that can also lead to obesity, hypertension, diabetes, and hyperlipidemia. These drugs also assist in increasing the high-density lipoprotein cholesterol in the body and preventing coronary heart conditions. Some of the commonly available antihyperlipidemic drugs include bile acid sequestrants, antihyperlipidemic agents, and cholesterol absorption inhibitors.
Download a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/antihyperlipidemic-drugs-market/requestsample
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Antihyperlipidemic Drugs Market Trends and Drivers:
The market is primarily driven by the rising cases of hyperlipidemia among individuals due to sedentary lifestyles, obesity, and consumption of fast foods. Additionally, the increasing geriatric population that is more susceptible to developing cardiovascular diseases represents another major growth-inducing factor.
Besides this, the growing prevalence of genetic, and acquired lipid and lipoprotein metabolism disorders among the pediatric population is further escalating the demand for antihyperlipidemic drugs to reduce hospitalization rates and premature deaths.
Furthermore, the growing awareness regarding complications related to hyperlipidemia is also propelling the market growth.
|Antihyperlipidemic Drugs Market Report Scope|
|Market size value in 2021||US$ 11.31 Billion|
|Market forecast in 2027||US$ 15.81 Billion|
|Growth Rate||CAGR of 5.20% from 2022 to 2027|
|Base year for estimation||2021|
Global Antihyperlipidemic Drugs Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
List Of Major Key Players :
Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.
The report has segmented the market on the basis of region, drug class, route of administration and distribution channel.
Breakup by Drug Class:
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- PCSK9 Inhibitors
Breakup by Route of Administration:
Market Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Stores
- Online Retailers
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/antihyperlipidemic-drugs-market
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.